by Jakub Jarolím, Business Intelligence Department
Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).
Sotio Biotech
15/9/2022
August 2022 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions
Market
Biotech stocks bounce in August as M&A activity increases
Biopharma stocks climb on upcoming filings, strong data, and potential mergers. NBI closed in August at same level as in the beginning of month but is still 14 % above the lowest point in June. Asset sales, reverse mergers, M&A and several positive datasets helped lift the biotech stocks up.
Antibody-Drug Conjugates
Enhertu gains expanded label in new class of HER2-low breast cancer patients
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.
Interleukin-15 and Interleukin-2
Medicenna closed public offering raising $20 million to advance its interleukin pipeline
Sanofi is picking Innovent Biologics as its partner of choice in China for its top oncology candidates in a deal where Sanofi will take a €300 million ($307 million) equity stake in the biotech.
Cell Therapies
Abecma from BMS shows survival benefit in earlier multiple myeloma patients
BMS and 2seventybio announced positive topline results from KarMMa-3 global Phase 3 randomized, multicenter, open-label study evaluating Abecma (idecabtagene vicleucel) compared to standard combination regimens in adults with multiple myeloma that is relapsed and refractory after two to four prior lines of therapy and refractory to the last regimen.
Other Innovative Treatment Areas
Keytruda missed in liver and prostate cancer Phase 3 trials
Merck & Co. said Keytruda pembrolizumab failed to meet its endpoints in two Phase 3 trials, one in patients with unresectable hepatocellular carcinoma and the other to treat metastatic castration-resistant prostate cancer.
Oncology Transactions
GSK receives licensing option to an ADC from Mersana for $100 million upfront
Mersana announced a global collaboration that provides GSK an exclusive option to co-develop and commercialize XMT-2056, an Immunosynthen ADC that targets a novel epitope of HER2.
DISCLAIMER / SOTIO
Legal Notice
The material contained in this document was prepared based on information from public and private sources that SOTIO believes to be reliable. It is protected by copyright law and cannot be further disseminated or used for any commercial purposes without SOTIO´s prior written consent.
Share on social networks